nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—PLK3—pancreas—bile duct cancer	0.00974	0.0309	CbGeAlD
Ruxolitinib—PRKG2—liver—bile duct cancer	0.00828	0.0263	CbGeAlD
Ruxolitinib—PRKCE—liver—bile duct cancer	0.00773	0.0246	CbGeAlD
Ruxolitinib—JAK1—pancreas—bile duct cancer	0.00747	0.0237	CbGeAlD
Ruxolitinib—PLK1—liver—bile duct cancer	0.00742	0.0236	CbGeAlD
Ruxolitinib—RPS6KA6—liver—bile duct cancer	0.00742	0.0236	CbGeAlD
Ruxolitinib—CAMK1D—pancreas—bile duct cancer	0.00729	0.0232	CbGeAlD
Ruxolitinib—HIPK2—pancreas—bile duct cancer	0.00697	0.0222	CbGeAlD
Ruxolitinib—DAPK3—pancreas—bile duct cancer	0.0067	0.0213	CbGeAlD
Ruxolitinib—PLK3—liver—bile duct cancer	0.0062	0.0197	CbGeAlD
Ruxolitinib—NUAK2—pancreas—bile duct cancer	0.00597	0.019	CbGeAlD
Ruxolitinib—PRKCE—lymph node—bile duct cancer	0.00592	0.0188	CbGeAlD
Ruxolitinib—CAMK1—liver—bile duct cancer	0.00579	0.0184	CbGeAlD
Ruxolitinib—PLK1—lymph node—bile duct cancer	0.00569	0.0181	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—bile duct cancer	0.00569	0.0181	CbGeAlD
Ruxolitinib—CAMK2G—pancreas—bile duct cancer	0.00559	0.0178	CbGeAlD
Ruxolitinib—TAOK2—liver—bile duct cancer	0.00521	0.0165	CbGeAlD
Ruxolitinib—TYK2—pancreas—bile duct cancer	0.00494	0.0157	CbGeAlD
Ruxolitinib—MKNK2—pancreas—bile duct cancer	0.00488	0.0155	CbGeAlD
Ruxolitinib—IRAK1—pancreas—bile duct cancer	0.00488	0.0155	CbGeAlD
Ruxolitinib—JAK1—liver—bile duct cancer	0.00475	0.0151	CbGeAlD
Ruxolitinib—PLK3—lymph node—bile duct cancer	0.00475	0.0151	CbGeAlD
Ruxolitinib—CAMK1D—liver—bile duct cancer	0.00464	0.0147	CbGeAlD
Ruxolitinib—PHKG2—liver—bile duct cancer	0.00461	0.0147	CbGeAlD
Ruxolitinib—LTK—lymph node—bile duct cancer	0.00459	0.0146	CbGeAlD
Ruxolitinib—STK16—liver—bile duct cancer	0.00446	0.0142	CbGeAlD
Ruxolitinib—CAMK1—lymph node—bile duct cancer	0.00444	0.0141	CbGeAlD
Ruxolitinib—HIPK2—liver—bile duct cancer	0.00444	0.0141	CbGeAlD
Ruxolitinib—MARK2—lymph node—bile duct cancer	0.00431	0.0137	CbGeAlD
Ruxolitinib—DAPK3—liver—bile duct cancer	0.00426	0.0135	CbGeAlD
Ruxolitinib—CLK2—liver—bile duct cancer	0.00422	0.0134	CbGeAlD
Ruxolitinib—ROCK1—liver—bile duct cancer	0.00409	0.013	CbGeAlD
Ruxolitinib—DYRK1A—liver—bile duct cancer	0.00399	0.0127	CbGeAlD
Ruxolitinib—TAOK2—lymph node—bile duct cancer	0.00399	0.0127	CbGeAlD
Ruxolitinib—BMPR2—liver—bile duct cancer	0.00398	0.0126	CbGeAlD
Ruxolitinib—TAOK3—pancreas—bile duct cancer	0.00395	0.0125	CbGeAlD
Ruxolitinib—NUAK2—liver—bile duct cancer	0.0038	0.0121	CbGeAlD
Ruxolitinib—JAK3—lymph node—bile duct cancer	0.00367	0.0117	CbGeAlD
Ruxolitinib—DCLK1—lymph node—bile duct cancer	0.00364	0.0116	CbGeAlD
Ruxolitinib—JAK1—lymph node—bile duct cancer	0.00364	0.0116	CbGeAlD
Ruxolitinib—PLK4—lymph node—bile duct cancer	0.00362	0.0115	CbGeAlD
Ruxolitinib—CAMK2G—liver—bile duct cancer	0.00356	0.0113	CbGeAlD
Ruxolitinib—BMP2K—liver—bile duct cancer	0.00356	0.0113	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—bile duct cancer	0.00356	0.0113	CbGeAlD
Ruxolitinib—PHKG2—lymph node—bile duct cancer	0.00354	0.0112	CbGeAlD
Ruxolitinib—LRRK2—liver—bile duct cancer	0.00353	0.0112	CbGeAlD
Ruxolitinib—DAPK2—lymph node—bile duct cancer	0.00348	0.011	CbGeAlD
Ruxolitinib—STK16—lymph node—bile duct cancer	0.00342	0.0109	CbGeAlD
Ruxolitinib—HIPK2—lymph node—bile duct cancer	0.0034	0.0108	CbGeAlD
Ruxolitinib—DAPK3—lymph node—bile duct cancer	0.00327	0.0104	CbGeAlD
Ruxolitinib—CLK2—lymph node—bile duct cancer	0.00324	0.0103	CbGeAlD
Ruxolitinib—MAP3K2—liver—bile duct cancer	0.00323	0.0103	CbGeAlD
Ruxolitinib—MAP3K7—liver—bile duct cancer	0.0032	0.0102	CbGeAlD
Ruxolitinib—TYK2—liver—bile duct cancer	0.00314	0.00999	CbGeAlD
Ruxolitinib—MKNK2—liver—bile duct cancer	0.0031	0.00986	CbGeAlD
Ruxolitinib—IRAK1—liver—bile duct cancer	0.0031	0.00986	CbGeAlD
Ruxolitinib—DYRK1A—lymph node—bile duct cancer	0.00306	0.00973	CbGeAlD
Ruxolitinib—BMPR2—lymph node—bile duct cancer	0.00305	0.00969	CbGeAlD
Ruxolitinib—NUAK2—lymph node—bile duct cancer	0.00291	0.00926	CbGeAlD
Ruxolitinib—JAK2—liver—bile duct cancer	0.00286	0.00909	CbGeAlD
Ruxolitinib—MAP3K3—liver—bile duct cancer	0.00276	0.00876	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—bile duct cancer	0.00273	0.00867	CbGeAlD
Ruxolitinib—BMP2K—lymph node—bile duct cancer	0.00273	0.00867	CbGeAlD
Ruxolitinib—LRRK2—lymph node—bile duct cancer	0.0027	0.00859	CbGeAlD
Ruxolitinib—TAOK3—liver—bile duct cancer	0.00251	0.00798	CbGeAlD
Ruxolitinib—MAP3K2—lymph node—bile duct cancer	0.00248	0.00787	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—bile duct cancer	0.00245	0.0078	CbGeAlD
Ruxolitinib—TYK2—lymph node—bile duct cancer	0.00241	0.00766	CbGeAlD
Ruxolitinib—IRAK1—lymph node—bile duct cancer	0.00238	0.00756	CbGeAlD
Ruxolitinib—MKNK2—lymph node—bile duct cancer	0.00238	0.00756	CbGeAlD
Ruxolitinib—RET—lymph node—bile duct cancer	0.00232	0.00737	CbGeAlD
Ruxolitinib—JAK2—lymph node—bile duct cancer	0.00219	0.00697	CbGeAlD
Ruxolitinib—MAP3K3—lymph node—bile duct cancer	0.00211	0.00672	CbGeAlD
Ruxolitinib—TAOK3—lymph node—bile duct cancer	0.00193	0.00612	CbGeAlD
Ruxolitinib—CYP3A4—liver—bile duct cancer	0.000763	0.00243	CbGeAlD
Ruxolitinib—JAK1—Innate Immune System—HRAS—bile duct cancer	5.5e-05	8.02e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EGFR—bile duct cancer	5.49e-05	8.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HRAS—bile duct cancer	5.48e-05	8e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EGFR—bile duct cancer	5.47e-05	7.98e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—KRAS—bile duct cancer	5.41e-05	7.89e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—bile duct cancer	5.4e-05	7.88e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—NRAS—bile duct cancer	5.39e-05	7.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—HRAS—bile duct cancer	5.39e-05	7.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—NRAS—bile duct cancer	5.38e-05	7.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MMP9—bile duct cancer	5.37e-05	7.83e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFBR2—bile duct cancer	5.34e-05	7.79e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—ERBB2—bile duct cancer	5.31e-05	7.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SMAD4—bile duct cancer	5.31e-05	7.75e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—bile duct cancer	5.26e-05	7.68e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—bile duct cancer	5.25e-05	7.66e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOS2—bile duct cancer	5.21e-05	7.61e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EGFR—bile duct cancer	5.21e-05	7.6e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—bile duct cancer	5.19e-05	7.58e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—KRAS—bile duct cancer	5.19e-05	7.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFBR2—bile duct cancer	5.18e-05	7.56e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—TGFB1—bile duct cancer	5.17e-05	7.55e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—KRAS—bile duct cancer	5.17e-05	7.54e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—NRAS—bile duct cancer	5.17e-05	7.54e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—HRAS—bile duct cancer	5.16e-05	7.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—bile duct cancer	5.16e-05	7.53e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—GNAS—bile duct cancer	5.15e-05	7.51e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—ERBB2—bile duct cancer	5.12e-05	7.48e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—NRAS—bile duct cancer	5.09e-05	7.42e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—bile duct cancer	5.08e-05	7.41e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—EGFR—bile duct cancer	5.07e-05	7.4e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EGFR—bile duct cancer	5.07e-05	7.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EGFR—bile duct cancer	5.05e-05	7.37e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SMAD4—bile duct cancer	5.05e-05	7.37e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EGFR—bile duct cancer	5.03e-05	7.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFBR2—bile duct cancer	5.03e-05	7.33e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—GNAS—bile duct cancer	5e-05	7.29e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—bile duct cancer	4.94e-05	7.21e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—KRAS—bile duct cancer	4.92e-05	7.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EGFR—bile duct cancer	4.91e-05	7.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SMAD4—bile duct cancer	4.91e-05	7.16e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EGFR—bile duct cancer	4.9e-05	7.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—HRAS—bile duct cancer	4.88e-05	7.12e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—HRAS—bile duct cancer	4.86e-05	7.09e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—GNAS—bile duct cancer	4.85e-05	7.08e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—HRAS—bile duct cancer	4.83e-05	7.04e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—KRAS—bile duct cancer	4.79e-05	6.99e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—KRAS—bile duct cancer	4.79e-05	6.99e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—NRAS—bile duct cancer	4.79e-05	6.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—KRAS—bile duct cancer	4.77e-05	6.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—NRAS—bile duct cancer	4.76e-05	6.95e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SMAD4—bile duct cancer	4.76e-05	6.94e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—KRAS—bile duct cancer	4.75e-05	6.93e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—NRAS—bile duct cancer	4.71e-05	6.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—EGFR—bile duct cancer	4.71e-05	6.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—bile duct cancer	4.67e-05	6.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—NRAS—bile duct cancer	4.67e-05	6.81e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—bile duct cancer	4.65e-05	6.78e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—KRAS—bile duct cancer	4.64e-05	6.77e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EGFR—bile duct cancer	4.63e-05	6.76e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—KRAS—bile duct cancer	4.63e-05	6.76e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—bile duct cancer	4.62e-05	6.74e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—HRAS—bile duct cancer	4.6e-05	6.71e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—bile duct cancer	4.59e-05	6.7e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—KRAS—bile duct cancer	4.45e-05	6.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TGFB1—bile duct cancer	4.42e-05	6.45e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HRAS—bile duct cancer	4.41e-05	6.44e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—bile duct cancer	4.4e-05	6.42e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MMP9—bile duct cancer	4.39e-05	6.41e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HRAS—bile duct cancer	4.39e-05	6.41e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—KRAS—bile duct cancer	4.38e-05	6.39e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—NRAS—bile duct cancer	4.38e-05	6.39e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ERBB2—bile duct cancer	4.37e-05	6.38e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—EGFR—bile duct cancer	4.36e-05	6.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TGFB1—bile duct cancer	4.34e-05	6.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EGFR—bile duct cancer	4.34e-05	6.33e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—ERBB2—bile duct cancer	4.32e-05	6.31e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EGFR—bile duct cancer	4.29e-05	6.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ERBB2—bile duct cancer	4.25e-05	6.2e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—bile duct cancer	4.22e-05	6.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—NRAS—bile duct cancer	4.2e-05	6.13e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—bile duct cancer	4.2e-05	6.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HRAS—bile duct cancer	4.18e-05	6.1e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—KRAS—bile duct cancer	4.12e-05	6.02e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ERBB2—bile duct cancer	4.12e-05	6.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—KRAS—bile duct cancer	4.1e-05	5.98e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—bile duct cancer	4.07e-05	5.94e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—bile duct cancer	4.07e-05	5.94e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—bile duct cancer	4.06e-05	5.92e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—KRAS—bile duct cancer	4.05e-05	5.92e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NRAS—bile duct cancer	4.04e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—bile duct cancer	4.04e-05	5.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—KRAS—bile duct cancer	4.02e-05	5.86e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—bile duct cancer	4e-05	5.84e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—bile duct cancer	3.99e-05	5.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS2—bile duct cancer	3.95e-05	5.77e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—bile duct cancer	3.95e-05	5.76e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—bile duct cancer	3.94e-05	5.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFBR2—bile duct cancer	3.93e-05	5.73e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERBB2—bile duct cancer	3.92e-05	5.72e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—bile duct cancer	3.9e-05	5.69e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NRAS—bile duct cancer	3.9e-05	5.69e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—bile duct cancer	3.9e-05	5.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—bile duct cancer	3.88e-05	5.67e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—bile duct cancer	3.87e-05	5.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—bile duct cancer	3.83e-05	5.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—bile duct cancer	3.83e-05	5.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GNAS—bile duct cancer	3.79e-05	5.53e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—bile duct cancer	3.78e-05	5.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—bile duct cancer	3.78e-05	5.51e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—bile duct cancer	3.77e-05	5.5e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KRAS—bile duct cancer	3.77e-05	5.5e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TGFB1—bile duct cancer	3.75e-05	5.48e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—bile duct cancer	3.72e-05	5.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB2—bile duct cancer	3.72e-05	5.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SMAD4—bile duct cancer	3.72e-05	5.42e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MMP9—bile duct cancer	3.71e-05	5.41e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—bile duct cancer	3.68e-05	5.37e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB2—bile duct cancer	3.66e-05	5.34e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TGFB1—bile duct cancer	3.62e-05	5.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KRAS—bile duct cancer	3.62e-05	5.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—bile duct cancer	3.57e-05	5.21e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—bile duct cancer	3.56e-05	5.2e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—bile duct cancer	3.55e-05	5.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—NRAS—bile duct cancer	3.54e-05	5.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—bile duct cancer	3.5e-05	5.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—bile duct cancer	3.48e-05	5.08e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—bile duct cancer	3.48e-05	5.07e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—bile duct cancer	3.45e-05	5.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—bile duct cancer	3.42e-05	4.98e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—bile duct cancer	3.35e-05	4.89e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—bile duct cancer	3.35e-05	4.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—bile duct cancer	3.33e-05	4.86e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NRAS—bile duct cancer	3.33e-05	4.86e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—bile duct cancer	3.3e-05	4.81e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NRAS—bile duct cancer	3.29e-05	4.8e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NRAS—bile duct cancer	3.23e-05	4.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—bile duct cancer	3.22e-05	4.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB2—bile duct cancer	3.22e-05	4.7e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—bile duct cancer	3.2e-05	4.67e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—bile duct cancer	3.19e-05	4.66e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—bile duct cancer	3.14e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NRAS—bile duct cancer	3.13e-05	4.57e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—bile duct cancer	3.08e-05	4.49e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—bile duct cancer	3.06e-05	4.47e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—bile duct cancer	3.06e-05	4.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—bile duct cancer	3.04e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—bile duct cancer	3.03e-05	4.42e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—bile duct cancer	3e-05	4.37e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—bile duct cancer	2.98e-05	4.35e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—bile duct cancer	2.98e-05	4.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—bile duct cancer	2.97e-05	4.34e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—bile duct cancer	2.96e-05	4.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—bile duct cancer	2.94e-05	4.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—bile duct cancer	2.94e-05	4.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—bile duct cancer	2.91e-05	4.24e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—IDH2—bile duct cancer	2.9e-05	4.24e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—bile duct cancer	2.86e-05	4.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—bile duct cancer	2.86e-05	4.17e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—bile duct cancer	2.85e-05	4.16e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—bile duct cancer	2.83e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—bile duct cancer	2.83e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—bile duct cancer	2.83e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—bile duct cancer	2.83e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—bile duct cancer	2.78e-05	4.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—bile duct cancer	2.78e-05	4.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—bile duct cancer	2.77e-05	4.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—bile duct cancer	2.75e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—bile duct cancer	2.73e-05	3.98e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—bile duct cancer	2.72e-05	3.97e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—bile duct cancer	2.7e-05	3.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—bile duct cancer	2.68e-05	3.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—bile duct cancer	2.66e-05	3.89e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—bile duct cancer	2.63e-05	3.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—bile duct cancer	2.59e-05	3.77e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—bile duct cancer	2.59e-05	3.77e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—bile duct cancer	2.58e-05	3.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—bile duct cancer	2.57e-05	3.75e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—bile duct cancer	2.54e-05	3.7e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—bile duct cancer	2.52e-05	3.67e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—IDH1—bile duct cancer	2.5e-05	3.65e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—bile duct cancer	2.48e-05	3.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—bile duct cancer	2.45e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—bile duct cancer	2.44e-05	3.56e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—bile duct cancer	2.44e-05	3.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—bile duct cancer	2.43e-05	3.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—bile duct cancer	2.43e-05	3.54e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—bile duct cancer	2.41e-05	3.51e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—bile duct cancer	2.4e-05	3.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—bile duct cancer	2.36e-05	3.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—bile duct cancer	2.36e-05	3.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—bile duct cancer	2.33e-05	3.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—bile duct cancer	2.31e-05	3.37e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—bile duct cancer	2.3e-05	3.36e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—bile duct cancer	2.29e-05	3.35e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—bile duct cancer	2.28e-05	3.33e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—bile duct cancer	2.26e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—bile duct cancer	2.26e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—bile duct cancer	2.23e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—bile duct cancer	2.19e-05	3.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—bile duct cancer	2.18e-05	3.18e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—bile duct cancer	2.16e-05	3.16e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—bile duct cancer	2.15e-05	3.14e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—bile duct cancer	2.13e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—bile duct cancer	2.11e-05	3.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—bile duct cancer	2.1e-05	3.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—bile duct cancer	2.09e-05	3.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—bile duct cancer	2.09e-05	3.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—bile duct cancer	2.08e-05	3.04e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—bile duct cancer	2.07e-05	3.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—bile duct cancer	2.06e-05	3.01e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—bile duct cancer	2.04e-05	2.97e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—bile duct cancer	2.03e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—bile duct cancer	2e-05	2.92e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—bile duct cancer	1.98e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—bile duct cancer	1.96e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—bile duct cancer	1.96e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—bile duct cancer	1.95e-05	2.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—bile duct cancer	1.95e-05	2.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—bile duct cancer	1.94e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—bile duct cancer	1.9e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—bile duct cancer	1.88e-05	2.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—bile duct cancer	1.88e-05	2.74e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—bile duct cancer	1.85e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—bile duct cancer	1.85e-05	2.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—bile duct cancer	1.8e-05	2.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—bile duct cancer	1.79e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—bile duct cancer	1.78e-05	2.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—bile duct cancer	1.74e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—bile duct cancer	1.71e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—bile duct cancer	1.65e-05	2.41e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC5A5—bile duct cancer	1.65e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—bile duct cancer	1.65e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—bile duct cancer	1.6e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—bile duct cancer	1.58e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—bile duct cancer	1.58e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—bile duct cancer	1.57e-05	2.3e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—bile duct cancer	1.55e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—bile duct cancer	1.53e-05	2.23e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—bile duct cancer	1.51e-05	2.2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—bile duct cancer	1.48e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—bile duct cancer	1.47e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—bile duct cancer	1.46e-05	2.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—bile duct cancer	1.44e-05	2.1e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—bile duct cancer	1.42e-05	2.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—bile duct cancer	1.36e-05	1.99e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNAS—bile duct cancer	1.28e-05	1.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—bile duct cancer	1.21e-05	1.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—bile duct cancer	1.16e-05	1.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—bile duct cancer	1.11e-05	1.62e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—bile duct cancer	6.88e-06	1e-05	CbGpPWpGaD
